New hope drug enters human testing for Tough-to-Treat cancers
NCT ID NCT04419532
Summary
This is the first study in humans testing a new drug called DS-1055a. It aims to find a safe dose and check for side effects in 40 adults with advanced solid tumors that have returned or stopped responding to available treatments. The main goal is to understand how the body handles the drug and what side effects might occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Institute Hospital of JFCR
Kōtoku, 135-8550, Japan
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Chūōku, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, 277-8577, Japan
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2C1, Canada
-
University of Cincinnati Cancer Center
Cincinnati, Ohio, 45219, United States
Conditions
Explore the condition pages connected to this study.